SynthesisFuture oncology (London, England)2025

The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis.

Zeyi Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.